TNF-α: A link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease

Lupus

Volumn 12, Issue 6, 2003, Pages 454-461

  Svenungsson, Elisabet ^a,d   Fei, G Z ^a   Jensen Urstad, K ^b   De Faire, U ^c   Hamsten, A ^c   Frostegard J ^a  

^a Unit of Rheumatology   (Sweden)

^b Department of Clinical Physiology ^*  (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; Lipoproteins; SLE; TNF receptor; TNF

Indexed keywords

TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTHROPOMETRY; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0038268826     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu412oa     Document Type: Article

References (39)

1. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-225.
2. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-415.
3. Svenungsson E, Jensen-Urstad K, Heimburger M et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887-1893.
4. Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 1999; 26(Suppl 57): 7-15.
5. Aderka D, Wysenbeek A, Engelmann H et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis and Rheumatism 1993; 36: 1111-1119.
6. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 1067-1074.
7. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579-580.
8. Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 2002; 112: 275-280.
9. Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 1999; 107: 119-125.
10. Jovinge S, Hamsten A, Tomvall P et al. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 1998; 47: 113-118.
11. Frostegard J, Ulfgren AK, Nyberg P et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Thl) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145: 33-43.
12. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 1995; 748: 501-507.
13. Frostegard J, Huang YH, Ronnelid J, Schafer-Elinder L. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol 1997; 17: 963-968.
14. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
15. Liang MH, Socher SA, Roberts WN, Esdaile JM. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 1988; 31: 817-825.
16. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology Damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BR, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance beta-cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
18. Lemne C, Jogestrand T, de Faire U. Carotid intima-media thickness and plaque in borderline hypertension. Stroke 1995; 26: 34-39.
19. Carlson K. Lipoprotein fractionation. J Clin Pathol Suppl 1973; 5: 32-37.
20. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-2153.
21. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-1890.
22. Grossman GB, Rohde LE, Clausell N. Evidence for increased peripheral production of tumor necrosis factor-alpha in advanced congestive heart failure. Am J Cardiol 2001; 88: 578-581.
23. Manzi S, Selzer F, Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51-60.
24. Sturfelt G, Sjoholm AG. Complement components, complement activation, and acute phase response in systemic lupus erythematosus. Int Arch Allergy Appl Immunol 1984; 75: 75-83.
25. Gabay C, Cakir N, Moral F et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997; 24: 303-308.
26. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24: 445-451.
27. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002; 29: 62-67.
28. Ilowite NT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988; 31: 859-863.
29. Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6: 533-539.
30. Ettinger WH, Klinefelter HF, Kwiterovitch PO. Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atheroselerosis 1987; 63: 167-172.
31. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med 1985; 312: 1544-1548.
32. Al-Khalili F, Svane B, Janszky I, Ryden L, Orth-Gomer K, Schenck-Gustafsson K. Significant predictors of poor prognosis in women aged ≤65 years hospitalized for an acute coronary event. J Intern Med 2002; 252: 561-569.
33. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes 1992; 41: 97-101.
34. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988; 6: 1328-1334.
35. Beutler B, Grau GE. Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med 1993; 21: S423-S435.
36. Borba EF, Bonfa E, Vinagre CG, Ramires JA, Maranhao RC. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1033-1040.
37. Skoog T, Dichtl W, Boquist S et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 2002; 23: 376-383.
38. Choy JC, Granville DJ, Hunt DW, McManus BM. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 2001; 33: 1673-1690.
39. Targher G, Zenari L, Bertolini L, Falezza G, Muggeo M, Zoppini G. Plasma total homocysteine levels are associated with von Willebrand factor, soluble intercellular adhesion molecule-1, and soluble tumor necrosis factor-alpha receptors in young type 1 diabetic patients without clinical evidence of macrovascular complications. Diabetes Care 2001; 24: 1496-1497.